Faculty Opinions recommendation of Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726024829.793512570 ◽

2015 ◽

Author(s):

Neil Ampel

Keyword(s):

Filamentous Fungi ◽

Primary Treatment ◽

Phase 3 ◽

Randomised Controlled

Download Full-text

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

10.1016/s0140-6736(15)01159-9 ◽

2016 ◽

Vol 387 (10020) ◽

pp. 760-769 ◽

Author(s):

Johan A Maertens ◽

Issam I Raad ◽

Kieren A Marr ◽

Thomas F Patterson ◽

Dimitrios P Kontoyiannis ◽

...

Keyword(s):

Filamentous Fungi ◽

Primary Treatment ◽

Phase 3 ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726024829.793532783 ◽

2017 ◽

Author(s):

John Wingard ◽

Maxim Norkin

Keyword(s):

Filamentous Fungi ◽

Primary Treatment ◽

Phase 3 ◽

Randomised Controlled

Download Full-text

Efficacy and safety outcomes in patients with probable or proven versus possible invasive mould disease from the phase 3 secure study, evaluating isavuconazole versus voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi

10.26226/morressier.56d5ba24d462b80296c949e9 ◽

2016 ◽

Author(s):

Johan Maertens

Keyword(s):

Filamentous Fungi ◽

Invasive Fungal Disease ◽

Primary Treatment ◽

Fungal Disease ◽

Efficacy And Safety ◽

Phase 3 ◽

Safety Outcomes

Download Full-text

Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial

10.1016/s0140-6736(21)00219-1 ◽

2021 ◽

Vol 397 (10273) ◽

pp. 499-509

Author(s):

Johan A Maertens ◽

Galia Rahav ◽

Dong-Gun Lee ◽

Alfredo Ponce-de-León ◽

Isabel Cristina Ramírez Sánchez ◽

...

Keyword(s):

Invasive Aspergillosis ◽

Primary Treatment ◽

Phase 3 ◽

Randomised Controlled

Download Full-text

Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial

10.1016/s0140-6736(18)32003-8 ◽

2019 ◽

Vol 393 (10176) ◽

pp. 1128-1137 ◽

Author(s):

Hiromichi Hamada ◽

Hiroyuki Suzuki ◽

Yoshihiro Onouchi ◽

Ryota Ebata ◽

Masaru Terai ◽

...

Keyword(s):

Coronary Artery ◽

Kawasaki Disease ◽

Intravenous Immunoglobulin ◽

Primary Treatment ◽

Phase 3 ◽

Coronary Artery Abnormalities ◽

Increased Risk ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1166102.628092 ◽

2009 ◽

Author(s):

Jim Orr ◽

Fadi Abu Shahin

Keyword(s):

Ovarian Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Advanced Ovarian Cancer ◽

Phase 3 ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13827960.15267062 ◽

2012 ◽

Author(s):

Weijing Sun ◽

Davendra Sohal

Keyword(s):

Gastric Cancer ◽

Randomised Controlled Trial ◽

Controlled Trial ◽

Phase 3 ◽

D2 Gastrectomy ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717969433.793480577 ◽

2013 ◽

Author(s):

Nancy Lin ◽

Ines Vaz-Luis

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Her2 Positive ◽

Phase 3 ◽

Her2 Positive Breast Cancer ◽

Randomised Controlled ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718302523.793494710 ◽

2014 ◽

Author(s):

Anthony Harries

Keyword(s):

Randomised Controlled Trial ◽

Clinical Outcomes ◽

Antiretroviral Treatment ◽

Controlled Trial ◽

Phase 3 ◽

Delayed Initiation ◽

Randomised Controlled ◽

Download Full-text

Faculty Opinions recommendation of Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725797184.793534680 ◽

2017 ◽

Author(s):

Wee Joo Chng

Keyword(s):

Retinoic Acid ◽

Arsenic Trioxide ◽

Acute Promyelocytic Leukaemia ◽

Acid Treatment ◽

Risk Groups ◽

Retinoic Acid Treatment ◽

Phase 3 ◽

Trans Retinoic Acid ◽

All Trans Retinoic Acid ◽

Randomised Controlled

Download Full-text